Home » Watson’s Generic Lidoderm Receives FDA Approval
Watson’s Generic Lidoderm Receives FDA Approval
Watson Pharmaceuticals announced that its subsidiary, Watson Laboratories, has received final approval from the FDA on its ANDA for lidocaine topical patch 5%, the generic equivalent to Endo’s Lidoderm.
The Sacramento Bee
The Sacramento Bee
Upcoming Events
-
07May
-
14May
-
30May